The provider-administered IL-23 inhibitor improved ACR20 response vs placebo after 2 doses in the phase 3 INSPIRE-1 and INSPIRE-2 trials.
|Articles|April 15, 2022
Daily OTC Pearl: Bismuth Subsalicylate Stomach Relief
Author(s)Saro Arakelians, PharmD
Bismuth subsalicylate is indicated for heartburn, indigestion, and upset stomach.
Advertisement
OTC/Lifestyle Pearl of the Day: Bismuth Subsalicylate Stomach Relief
Indication: Bismuth subsalicylate is indicated for heartburn, indigestion, and upset stomach.
Insight:
- Bismuth subsalicylate upset stomach reliever/antidiarrheal offers relief for 5 symptoms: heartburn, indigestion, upset stomach, nausea, and diarrhea.
- Each caplet contains calcium (27 mg); sodium (3 mg); salicylate (99 mg). The product is low sodium and sugar free.
- Active Ingredient: Bismuth subsalicylate (262 mg). Inactive Ingredients: Calcium carbonate, crospovidone, Fd&C Red 27 aluminum lake, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate.
- Swallow with water, do not chew. Adults and children 12 years of age and older take 2 caplets every half-hour to 1 hour as needed.
- Do not exceed 8 doses (16 caplets) in 24 hours. Use until diarrhea stops, but not more than 2 days. Children under 12 years, ask a physician.
- Drink plenty of clear fluid to help prevent diarrhea. Avoid excessive heat over 104 degrees F.
- Allergy Alert: Contains salicylate. Do not take if allergic to salicylates (including aspirin); taking other salicylate products.
Source:
Advertisement
Related to this article
Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg per day was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
3
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
4
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
5